Researchers at Hitgen Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have described Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.